ConductScience.org, home

Paper18752004

Vascular targeted therapies in oncology.

Siemann DW and 1 other. Cell Tissue Res, 2009. Cited by 72 papers, by iCite.

Cite this record

ConductScience Library. Vascular targeted therapies in oncology. Papers, record 18752004. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/18752004

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Vascular targeted therapies in oncology.
PubMed
Journal
Cell Tissue Res
PubMed
Year
2009
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Review
PubMed
Citations, by iCite
72
iCite
Relative citation ratio, by iCite
1.95
iCite
Revised in PubMed
2025-05-29
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Siemann DWDietmar W
2Horsman MRMichael R

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Angiogenesis InhibitorsMajor topic
NeoplasmsMajor topic
Neovascularization, PathologicMajor topic
Animals
Blood Vessels
Cell Death
Drug Delivery Systems
Humans
Oxygen

Source PubMed

Download CSV of topics

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
R01 CA084408NCI NIH HHSUnited StatesR01CA084408PubMed and NIHNIH RePORTER
R01 CA089655NCI NIH HHSUnited StatesR01CA089655PubMed and NIHNIH RePORTER
CA084408NCI NIH HHSUnited StatesR01CA084408PubMed and NIHNIH RePORTER
CA089655NCI NIH HHSUnited StatesR01CA089655PubMed and NIHNIH RePORTER

Download CSV of grants

References42

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
19845119Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid.Int J Radiat Oncol Biol Phys1998https://conductscience.org/library/papers/9845119PubMed
211173139In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment.Int J Radiat Oncol Biol Phys2001https://conductscience.org/library/papers/11173139PubMed
315928673Disrupting tumour blood vessels.Nat Rev Cancer2005https://conductscience.org/library/papers/15928673PubMed
415254283Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas.N Engl J Med2004https://conductscience.org/library/papers/15254283PubMed
515701823Differentiation and definition of vascular-targeted therapies.Clin Cancer Res2005https://conductscience.org/library/papers/15701823PubMed
615197790Vascular-targeting therapies for treatment of malignant disease.Cancer2004https://conductscience.org/library/papers/15197790PubMed
723484531An update on the clinical development of drugs to disable tumor vasculature.Expert Opin Drug Discov2007https://conductscience.org/library/papers/23484531PubMed
810466764Tumour vasculature as a target for cancer therapy.Br J Cancer1999https://conductscience.org/library/papers/10466764PubMed
915474333Therapeutic strategies that selectively target and disrupt established tumor vasculature.Hematol Oncol Clin North Am2004https://conductscience.org/library/papers/15474333PubMed
10165518625,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent.Clin Cancer Res2006https://conductscience.org/library/papers/16551862PubMed
1116818709Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity.Clin Cancer Res2006https://conductscience.org/library/papers/16818709PubMed
1212060643Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models.Clin Cancer Res2002https://conductscience.org/library/papers/12060643PubMed
1312778131Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma.Nat Rev Cancer2003https://conductscience.org/library/papers/12778131PubMed
1414760060Vascular targeting agents as cancer therapeutics.Clin Cancer Res2004https://conductscience.org/library/papers/14760060PubMed
1516224539Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling.J Clin Invest2005https://conductscience.org/library/papers/16224539PubMed
1612635171Specialization of tumour vasculature.Nat Rev Cancer2002https://conductscience.org/library/papers/12635171PubMed
1712067983A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer.Cancer Res2002https://conductscience.org/library/papers/12067983PubMed
1812516034Role of angiogenesis in tumor growth and metastasis.Semin Oncol2002https://conductscience.org/library/papers/12516034PubMed
1912499266ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature.Cancer Res2002https://conductscience.org/library/papers/12499266PubMed
20895546Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis.Microvasc Res1977https://conductscience.org/library/papers/895546PubMed

See all 42 referencesDownload CSV of references

Cited by39

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 72 citations.

PMIDTitleJournalYearIn PapersSource
42828053Fibrinogen-Drug Nanoparticles Achieve Durable Responses in Pancreatic and Breast Cancer Murine Models.ACS Pharmacol Transl Sci2026https://conductscience.org/library/papers/42828053PubMed
40529069Benzosuberene and Tetracyclic Analogues as Colchicine Site Inhibitors of Tubulin Polymerization.ACS Med Chem Lett2025https://conductscience.org/library/papers/40529069PubMed
39776800Vascularized tumor on a microfluidic chip to study mechanisms promoting tumor neovascularization and vascular targeted therapies.Theranostics2025https://conductscience.org/library/papers/39776800PubMed
39125647Targeting the Tumor Vascular Supply to Enhance Radiation Therapy Administered in Single or Clinically Relevant Fractionated Schedules.Int J Mol Sci2024https://conductscience.org/library/papers/39125647PubMed
37874534Targeting circulating tumor cells to prevent metastases.Hum Cell2024https://conductscience.org/library/papers/37874534PubMed
35935920Synthesis of a boron-containing amidoxime reagent and its application to synthesize functionalized oxadiazole and quinazolinone derivatives.Tetrahedron Lett2022https://conductscience.org/library/papers/35935920PubMed
357691063D-Cultured Vascular-Like Networks Enable Validation of Vascular Disruption Properties of Drugs In Vitro.Front Bioeng Biotechnol2022https://conductscience.org/library/papers/35769106PubMed
32706818Noninvasive imaging of tumor hypoxia after nanoparticle-mediated tumor vascular disruption.PLoS One2020https://conductscience.org/library/papers/32706818PubMed
32130518High glucose concentration produces a short-term increase in pERK1/2 and p85 proteins, having a direct angiogenetic effect by an action similar to VEGF.Acta Diabetol2020https://conductscience.org/library/papers/32130518PubMed
31799244Treatment of Hepatocellular Carcinoma by Intratumoral Injection of 125I-AA98 mAb and Its Efficacy Assessments by Molecular Imaging.Front Bioeng Biotechnol2019https://conductscience.org/library/papers/31799244PubMed
31676822Selective Priming of Tumor Blood Vessels by Radiation Therapy Enhances Nanodrug Delivery.Sci Rep2019https://conductscience.org/library/papers/31676822PubMed
31551349Longitudinal Photoacoustic Imaging of the Pharmacodynamic Effect of Vascular Targeted Therapy on Tumors.Clin Cancer Res2019https://conductscience.org/library/papers/31551349PubMed
29983002Spatiotemporal heterogeneity of tumor vasculature during tumor growth and antiangiogenic treatment: MRI assessment using permeability and blood volume parameters.Cancer Med2018https://conductscience.org/library/papers/29983002PubMed
28628642Nanoscale quantification of the biophysical characterization of combretastatin A-4-treated tumor cells using atomic force microscopy.PLoS One2017https://conductscience.org/library/papers/28628642PubMed
27347765Hepatocellular Carcinoma: Intra-arterial Delivery of Doxorubicin-loaded Hollow Gold Nanospheres for Photothermal Ablation-Chemoembolization Therapy in Rats.Radiology2016https://conductscience.org/library/papers/27347765PubMed
26983987The impact of hypoxia and its modification of the outcome of radiotherapy.J Radiat Res2016https://conductscience.org/library/papers/26983987PubMed
26745936Low Z target switching to increase tumor endothelial cell dose enhancement during gold nanoparticle-aided radiation therapy.Med Phys2016https://conductscience.org/library/papers/26745936PubMed
26700713Roadmap to Clinical Use of Gold Nanoparticles for Radiation Sensitization.Int J Radiat Oncol Biol Phys2016https://conductscience.org/library/papers/26700713PubMed
26418302Nanoparticle Mediated Tumor Vascular Disruption: A Novel Strategy in Radiation Therapy.Nano Lett2015https://conductscience.org/library/papers/26418302PubMed
26325604The vascular disrupting activity of OXi8006 in endothelial cells and its phosphate prodrug OXi8007 in breast tumor xenografts.Cancer Lett2015https://conductscience.org/library/papers/26325604PubMed

See all 39 cited byDownload CSV of cited by

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CDH51003PubTator's text mininghttps://conductscience.org/library/genes/1003NCBI Gene
KDR3791PubTator's text mininghttps://conductscience.org/library/genes/3791NCBI Gene
TNF7124PubTator's text mininghttps://conductscience.org/library/genes/7124NCBI Gene
TXK7294PubTator's text mininghttps://conductscience.org/library/genes/7294NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/18752004

GET https://conductscience.org/api/papers/v1/18752004/references?page=2